What’s Trending?

Eli Lilly has scored its next migraine drug approval. While its 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur. [...]
Fri, Oct 11, 2019
Source FiercePharma
Drug-cost watchdog Institute for Clinical and Economic Review (ICER) is out with its new draft assessment of JAK inhibitors to treat rheumatoid arthritis, which incorporates different assumptions about how physicians treat the disease and the time horizon that should be considered when reviewing the costs of the drugs. [...]
Fri, Oct 11, 2019
Source FiercePharma
Johnson & Johnson is facing not one but two major litigation roundups over sales of its opioids and talcum powder products, leaving its share price “historically cheap.” But even as a pair of massive settlements loom, one analyst says he sees an opportunity for investors. [...]
Fri, Oct 11, 2019
Source FiercePharma
Already behind in the PARP inhibitor race, Clovis Oncology's Rubraca has at least won a reserved backing from England's drug cost watchdog that helps level the playground in the U.K. region. Now, the late-comer will have to face two Big Pharma companies in their home country. [...]
Fri, Oct 11, 2019
Source FiercePharma
To date, MGB-BP-3 is the only antibiotic that has the killing power, combined with the speed of action, to eradicate the disease within the first few hours of exposure. [...]
Fri, Oct 11, 2019
Source PharmaTimes
The "state of the art" facility will be the new base for 500 of the 1,200 employees in the UK. [...]
Fri, Oct 11, 2019
Source PharmaTimes
The FDA claims to have found “unacceptable” levels of carcinogen in the medicine. [...]
Fri, Oct 11, 2019
Source PharmaTimes
The knock-on effects of these cuts has also seen an increase of over 61,000 hospital admissions since 2012 at an estimated cost of £317m to the NHS. [...]
Fri, Oct 11, 2019
Source PharmaTimes
FDA
The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated for the preventive treatment of migraine. [...]
Fri, Oct 11, 2019
Source WorldPharmaNews
A team led by a scientist at Scripps Research has invented a new genomics technique for tracking down the causes of rare genetic diseases. The technique, which the researchers report in Science, makes use of the fact that people inherit two copies or "alleles" of virtually every gene, one from [...]
Thu, Oct 10, 2019
Source WorldPharmaNews
Bayer
Bayer announced today that the company has signed collaboration agreements with eleven digital health startups. As part of the program, Bayer will support these startup companies aiming for longer-term collaborations to drive forward the development of specific digital solutions to improve patients' health in the fields of cardiovascular diseases, oncology, [...]
Thu, Oct 10, 2019
Source WorldPharmaNews
An artificial intelligence/machine learning model to predict which scientific advances are likely to eventually translate to the clinic has been developed by Ian Hutchins and colleagues in the Office of Portfolio Analysis (OPA), a team led by George Santangelo at the National Institutes of Health (NIH). This work, described in [...]
Wed, Oct 09, 2019
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews